Langerhans Cell Histiocytosis - 3 Studies Found
| Completed |
: Mirdametinib in Histiocytic Disorders : Langerhans Cell Histiocytosis (LCH) : 2025-09-01 : Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule.Consecu |
| Completed |
: LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study : Langerhans Cell Histiocytosis : 2025-09-01 : Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice. |
| COMPLETED |
: Denosumab for the Treatment of Adult LCH : Langerhans Cell Histiocytosis : 2025-09-01 : As already described in arm description |